Viveve Medical (NASDAQ: VIVE) announced its participation in the Alliance Group Partners Virtual Healthcare Symposium on November 19, 2020. CEO Scott Durbin will engage in one-on-one meetings with investors at the event. Viveve specializes in women’s intimate health solutions, utilizing its Viveve System that employs Cryogen-cooled Monopolar Radiofrequency technology. The company is advancing its clinical development for stress urinary incontinence, having received FDA approval for the PURSUIT Trial. For more details, visit viveve.com.
Viveve Medical (NASDAQ:VIVE) will release its Q3 2020 financial results on November 12, 2020, post-market closure, and will hold a conference call at 5:00 PM ET. The company is committed to enhancing women’s intimate health through innovative solutions, including the patented Viveve® System. This device is FDA cleared for surgical procedures and has received international approvals for vaginal laxity and sexual function indications.
Additionally, Viveve is advancing its clinical trial for stress urinary incontinence, supported by FDA approval for the pivotal PURSUIT trial.
ENGLEWOOD, CO / ACCESSWIRE / October 30, 2020 / Viveve Medical (NASDAQ: VIVE) announced the appointment of Dr. Sharon Collins Presnell to its board of directors and audit committee, effective October 28, 2020. This move aligns with Nasdaq's corporate governance requirements. Dr. Presnell brings extensive experience in academic and biotech sectors, ensuring robust strategic development in cellular therapies. Viveve is advancing its stress urinary incontinence clinical program and anticipates positive impacts from Dr. Presnell's expertise in the ongoing pivotal PURSUIT trial.
Viveve Medical, Inc. (NASDAQ:VIVE) announced the formation of a clinical advisory group of leading urology and urogynecology experts to guide its pivotal PURSUIT trial for Stress Urinary Incontinence (SUI). This elite Clinical Advisory Board will provide critical insights as Viveve develops its clinical strategy. The PURSUIT trial aims to evaluate Viveve's dual-energy technology, which has the potential to improve treatment outcomes for the estimated 25-30 million women affected by SUI. The study's positive results could support future U.S. indications for Viveve's treatment.
Viveve Medical has secured U.S. Patent No. 10,779,874 for its innovative treatment method addressing stress urinary incontinence (SUI)/b) in women. This patent enhances Viveve's intellectual property portfolio, essential as it prepares to launch the pivotal for SUI. The company's dual-energy technology aims to strengthen connective tissues and improve vaginal integrity. CEO Scott Durbin emphasized the unmet market need for non-invasive SUI treatments, reinforcing the potential for new indications pending regulatory approval.
ENGLEWOOD, CO / ACCESSWIRE / September 3, 2020 / Viveve Medical, Inc. (NASDAQ: VIVE) will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, from 11:30 AM to 12:00 PM ET. Due to the pandemic, the event will be held virtually. Scott Durbin, CEO, will also engage in one-on-one meetings. The presentation will be available live on the company's website, with an archived version accessible for 30 days post-event. Viveve focuses on women's intimate health, with FDA clearance for its Viveve System and ongoing clinical development for SUI treatments.
Viveve Medical, Inc. (NASDAQ:VIVE) has raised $3.6 million from the exercise of outstanding Series A, B, A-2, and B-2 warrants. This funding will support the upcoming pivotal PURSUIT Trial for stress urinary incontinence (SUI) in the U.S. The exercise represents approximately 61% of total outstanding warrants, contributing to a cash balance of $8.5 million as of June 30, 2020. Future exercises of remaining warrants could yield an additional $4.9 million. The company recently reported positive results from its SUI feasibility and preclinical studies.
Viveve Medical, Inc. (NASDAQ: VIVE) announced positive results from its three-arm feasibility study on Stress Urinary Incontinence (SUI), demonstrating significant efficacy of its Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment compared to an inert sham treatment. The trial involved 36 women and achieved its primary endpoint with a median change of -9.5g vs. -4.4g in the control. Additionally, preclinical data validated a new inert sham tip for the upcoming U.S. PURSUIT trial, which aims to further assess the treatment's effectiveness in a larger study.
Viveve Medical (NASDAQ:VIVE) reported Q2 2020 revenue of $704K, a decline from $1.1M in Q2 2019. The company faced challenges due to COVID-19 but achieved FDA clearance for the pivotal PURSUIT Trial aimed at treating stress urinary incontinence (SUI) in women. Operating expenses decreased to $4.6M from $8.4M year-over-year. The net loss was $8.1M or $0.57 per share, an improvement from a loss of $9.7M or $20.93 per share in 2019. Cash reserves stood at $8.5M.
Viveve Medical reported Q2 2020 revenue of $704 thousand, down from $1.1 million in Q2 2019, reflecting the impact of COVID-19. The company achieved FDA clearance for its pivotal SUI PURSUIT trial and advanced its SUI feasibility study, expected to have results this summer. Total operating expenses decreased to $4.6 million from $8.4 million year-over-year, partly due to organizational efficiencies. A net loss of $8.1 million was reported, equating to ($0.57) per share.